Cat.No：GM-88119MAB
Product ：Anti-IL-6 hIgG1 Reference Antibody (Clazabio)
Cat.No：GM-88119MAB
Product ：Anti-IL-6 hIgG1 Reference Antibody (Clazabio)
GM-88119MAB-1mg / 1 mg
GM-88119MAB-5mg / 5 mg
GM-88119MAB-25mg / 5 mg * 5 vials
GM-88119MAB-50mg / 50 mg
GM-88119MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | IL-6 |
Clone | Clazakizumab |
Alternative Names | BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2, IFNB2, IL6 |
Source/Isotype | Human IgG1 (N297A, REEM), Kappa |
Application | Block assay |
Description | Interleukin-6(IL-6) is a classic Proinflammatory cytokine. The gene for IL-6 is located on chromosome 7 and encodes a precursor protein that is spliced and glycated to produce secreted IL-6. IL-6 binds to membrane-bound IL-6R (mbIL-6R) , recruits GP130, and activates pathways such as Jak/STAT3, MAPK, PI3K/AKT. Abnormal IL-6 signaling is closely related to the pathological process of a variety of diseases, including autoimmune diseases, infectious inflammation, metabolic syndrome, and the tumor-associated inflammatory microenvironment, which may contribute to the pathogenesis of inflammatory diseases, is a key drug target for multiple targeted therapies, such as IL-6/IL-6R inhibitors. Clazakizumab (also written CLZ-05clz) is a humanized monoclonal antibody that targets IL6(IL-6) and inhibits il-6il-6r signaling by neutralizing IL-6. It belongs to a different target selection of the same inflammatory pathway intervention strategy with some drugs targeting IL-6R, such as tocilizumab, with potential application scenarios and unique pharmacokinetics safety profiles. |
Cat.No：GM-88119MAB
Product ：Anti-IL-6 hIgG1 Reference Antibody (Clazabio)
GM-88119MAB-1mg / 1 mg
GM-88119MAB-5mg / 5 mg
GM-88119MAB-25mg / 5 mg * 5 vials
GM-88119MAB-50mg / 50 mg
GM-88119MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | IL-6 |
Clone | Clazakizumab |
Alternative Names | BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2, IFNB2, IL6 |
Source/Isotype | Human IgG1 (N297A, REEM), Kappa |
Application | Block assay |
Description | Interleukin-6(IL-6) is a classic Proinflammatory cytokine. The gene for IL-6 is located on chromosome 7 and encodes a precursor protein that is spliced and glycated to produce secreted IL-6. IL-6 binds to membrane-bound IL-6R (mbIL-6R) , recruits GP130, and activates pathways such as Jak/STAT3, MAPK, PI3K/AKT. Abnormal IL-6 signaling is closely related to the pathological process of a variety of diseases, including autoimmune diseases, infectious inflammation, metabolic syndrome, and the tumor-associated inflammatory microenvironment, which may contribute to the pathogenesis of inflammatory diseases, is a key drug target for multiple targeted therapies, such as IL-6/IL-6R inhibitors. Clazakizumab (also written CLZ-05clz) is a humanized monoclonal antibody that targets IL6(IL-6) and inhibits il-6il-6r signaling by neutralizing IL-6. It belongs to a different target selection of the same inflammatory pathway intervention strategy with some drugs targeting IL-6R, such as tocilizumab, with potential application scenarios and unique pharmacokinetics safety profiles. |
